Edition:
United States

FDA Approves Dupixent (Dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis


Wednesday, 26 Jun 2019 01:29pm EDT 

June 26 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA APPROVES DUPIXENT® (DUPILUMAB) FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS.FDA APPROVED DUPIXENT (DUPILUMAB) FOR USE WITH OTHER MEDICINES TO TREAT CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS.